Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions develops and supplies cell processing tools and bioproduction products for the cell and gene therapy market and broader biopharma customers. Company news commonly covers financial results from continuing operations, demand for biopreservation media, and the role of its products in maintaining biologic material during collection, development, manufacturing, storage, distribution, and thawing.
Recurring updates also include product-portfolio expansion, supply agreements for cell and gene therapy manufacturing inputs, CellSeal vial systems, human platelet lysate products, cytokine and growth factor distribution, and research activity tied to biopreservation and cryopreservation technologies.
BioLife Solutions (Nasdaq: BLFS) reported Q1 2026 revenue of $27.5M, up 25% year-over-year, GAAP gross margin of 64%, GAAP net income of $1.2M, and non-GAAP adjusted EBITDA of $6.2M (22% of revenue). Cash, cash equivalents and marketable securities totaled $111.5M. The company reiterated 2026 revenue guidance of $112.5M–$115.0M and mid-60% gross margin.
BioLife Solutions (NASDAQ: BLFS) will release its Q1 2026 financial results on May 7, 2026 and host a conference call and live webcast at 4:30 PM ET (1:30 PM PT). Management will provide an overview of results and a general business update.
Investors can access the live webcast via the company Investor Relations earnings page. A replay will be posted about two hours after the call and archived for 90 days on the investor website.
BioLife Solutions (NASDAQ: BLFS) won the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system for frozen biologics.
Launched in 2025, CryoCase was designed to address documented cryobag failures by reinforcing structural protection during freezing, liquid nitrogen storage, distribution, and visual inspection while remaining compatible with closed system CGT workflows.
BioLife Solutions (Nasdaq: BLFS) reported fourth-quarter 2025 revenue from continuing operations of $24.8M (+20% YoY) and full-year 2025 revenue of $96.2M (+29% YoY). GAAP gross margin was 63% in Q4 and 65% for 2025; adjusted EBITDA was $6.9M (28% of revenue) in Q4 and $25.0M (26% of revenue) for 2025. Cash, cash equivalents, and marketable securities totaled $120.2M at year-end. The company completed the sale of evo for $25.5M in October 2025 and provided 2026 guidance of $112.5M–$115.0M revenue ( +17%–20%) with mid-60% GAAP gross margin and full-year GAAP net income expected.
Management highlighted market share positions in biopreservation media and plans for margin expansion and improved adjusted EBITDA in 2026.
BioLife Solutions (NASDAQ: BLFS) will report Q4 and full-year 2025 financial results on February 26, 2026 and hold a conference call and live webcast at 4:30pm ET (1:30pm PT).
Investors can access the live webcast on the company Investor Relations website and a replay will be archived for 90 days.
BioLife Solutions (NASDAQ: BLFS) entered a multi-year supply agreement with Qkine Limited to distribute cytokine and growth factor products for the cell and gene therapy (CGT) market. BioLife obtained exclusive worldwide distribution for specific Qkine products and non-exclusive rights to others. The companies will collaborate to package select Qkine products using BioLife's CellSeal® Connect vial system to support closed and automated CGT workflows. Third-party research cited estimates the global cytokines market at $500 million today, projected to reach $1 billion by 2030 on mid-teens CAGR.
BioLife Solutions (Nasdaq: BLFS) reported preliminary unaudited Q4 2025 revenue from continuing operations of $24.8M, up 20% from $20.7M in Q4 2024. Full-year 2025 preliminary unaudited revenue from continuing operations was $96.2M, up 29% from $74.6M in 2024 and slightly above the raised guidance high end of $96.0M (adjusted for the evo sale). Results exclude discontinued businesses and reflect a $1.3M biopreservation media shipment accelerated into Q3 at a customer's request. The company noted results are preliminary and unaudited and will finalize full 2025 financials when reporting complete results in February 2026.
BioLife Solutions (NASDAQ: BLFS) opened the Aby J. Mathew Center for Biopreservation Excellence at its expanded Bothell headquarters on November 20, 2025.
The 4,500 square foot facility combines state-of-the-art conference and laboratory space to showcase BioLife's cell processing product portfolio, provide customized training and customer workshops, support internal research, and generate applications data for current and pipeline products.
The Center will also support development of next-generation cryopreservation products that incorporate the company's proprietary ice recrystallization inhibitor (IRI) technology acquired earlier in 2025, and serve as a hub for industry collaboration and biopreservation best practices.
BioLife Solutions (NASDAQ: BLFS) announced that management will participate in multiple investor conferences in November and December 2025, including Raymond James Napa Small Cap Symposium on Nov 17, 2025, Stephens Annual Investment Conference on Nov 18–20, 2025, Jefferies Global Healthcare Conference on Nov 17–20, 2025, Furey Research Partners Hidden Gems Conference on Nov 24–25, 2025, Wolfe Research Small & Mid-Cap Conference on Dec 2–3, 2025, and Northland Growth Conference on Dec 16, 2025.
The company said its refreshed investor presentation is now available on the Investor Relations section of the company website.
BioLife Solutions (Nasdaq: BLFS) reported Q3 2025 results showing continued growth in its core cell processing business. Cell Processing revenue rose 33% YoY to $25.4M, total revenue was $28.1M (up 31% YoY), and adjusted EBITDA was $7.8M (28% of revenue). GAAP net income for Q3 was $0.6M. Management raised 2025 Cell Processing revenue guidance to $93.0M–$94.0M and total revenue guidance (post-evo sale) to $95.0M–$96.0M. The company completed the sale of its evo cold chain business for $25.5M in early October 2025.